(Date:7/3/2009)... that finding will lead to treatments, , ...rchers say they,ve found a major cellular flaw tha...er. , When caught early, lung cancer can often ...the disease is well advanced. Though doctors can s...e often springs back more virulent than ever, freq...
(Date:7/3/2009)... /PRNewswire-Asia/ -- Sundia MediTech, a leading,...ourcing company in Shanghai,China announced toda...e,President of Chemistry Services. , Prior...Biosciences, a drug,discovery and development com...,scientist to Senior Director of Medicinal Chemist...
(Date:7/3/2009)... Two companies and three individuals have been re...l international competition designed to reward wor...mber SafetyXChange.org community released its 2009... http://www.safetyxchange.org/saxcies-video . The ...ho dedicate their lives to keeping others safe - a...
(Date:7/3/2009)... Julian Whitaker, MD, a founder of the alternativ...rchjointpain.com, a new informational Web site dev... and solutions. , Potomac...a founder of the alternative health movement, is n... informational Web site devoted to all aspects of ...
Breaking Medicine News(10 mins):Health News:Cell Pathway May Be Key to Lung Cancer's Spread 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 3Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 2Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 3Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 4Health News:Dr. Julian Whitaker Featured on Searchjointpain.com 2...ld of stem cell technology further. Thailand will ...nds to verify the virtue, success and safety of st...isease. Experiments will be conducted on humans,...is study will be a fusion of efforts from the Depa...
...u strain was reported in a poultry farm near Pakis...ongoing surveillance for avian influenza, a suspec... Sihala, some 25 km from Islamabad on Friday," liv... commissioner Muhammad Afzal said. "Clinically, ...
...Marine Resources has dismissed the possibility of ...ated that the death of chickens in the Bondoukou r...s. The exact cause of the death is still unknown....ests conducted by Bingerville laboratory near Abid...
...V, a person is afflicted with, among the different...tor of how quickly// they will succumb to the dise...people in Uganda to reveal that those with subtype...n their health rather than subtype A -HIV In the...
Other Medicine News:(Date:6/29/2009)...Targets for Novel Biotherapeutics Based On Natural...ne 29 Pangu BioPharma, a subsidiar... filing of its third patent application on proprie...thetases. Although tRNA synthetases are universal...hinery found in all organisms, human synthetases h...
(Date:6/28/2009)...lif., June 29 Sangamo Bi...that a key research milestone has been achieved in..., Inc., a wholly-owned member of the Roche Group, ...teristics for pharmaceutical protein production pu...-binding protein nuclease (ZFN) technology. Genent...
(Date:6/28/2009)...AM, England and TOKYO, June 29 ,...ompanies , Sosei Group Corporation ("Sosei"...("Vectura"; LSE: VEC) announce the commencement of...237, a once-daily, long-acting muscarinic,antagon...e pulmonary disease,(COPD). NVA237 is a dry powde...
(Date:6/26/2009)... N.J., June 26 Sanofi-...been made aware of data associated with a retrospe...sults of these data clearly show that no definitiv...usal relationship between Lantus(R) (insulin glarg...lignancies, as the authors of the study point out....
Breaking Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3Therapy Could Save Limbs After Frostbite 14493 1Therapy Could Save Limbs After Frostbite 14493 2Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 14489 1Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 14489 2Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 14489 3Hillenbrand Industries Announces Formal Board Approval of Separation by Means of Share Distribution and Details for Completion 14489 4Sigma Aldrich To Hold Annual Business Review 4007 1U S Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 14486 1U S Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 14486 2U S Soccer Team Putting Vision in Focus for the Beijing 2008 Olympic Games 14486 3...NTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 25, 2007 ...pany dedicated to the,development and commercializ...t Abstract #2209-PO, Evaluation of Glycemic Parame...ermine and Topiramate:,Outcomes in a Private Pract...betes Association 2007 Scientific Sessions Abstrac...
...BRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - Eli...lication of clinical,data highlighting the ability...herapy, or combination therapy with metformin, to,...data were,published in the Abstract Book for the A...c Sessions in Chicago, Illinois.,Glufast is an ins...
Other Medicine Technology:VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 515mm Open Blades, Thumb Screw Control; in Titanium.
10mm from mid screw to tips; curved tips, in Titanium.
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel.
Retractable, straight double Lancet Blade, 15 Degree Angle , available in variations; Titanium handle
Medicine Products: